AMORFIX ANNOUNCES NEW PATENTS AWARDED FOR MISFOLDED SOD1 TARGETS

TSX: AMF

TORONTO, May 13 /CNW/ - Amorfix Life Sciences Ltd., a product development company focused on diagnostics and therapeutics for misfolded protein diseases, announced today that three patents to key targets for misfolded SOD1 have now been approved by the United States Patent and Trademark Office.

Amorfix's successful patenting of the SOD1 targets have particular importance for treatment of amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease, a key Amorfix program. The SOD1 protein is normally tightly packed into a specific three-dimensional shape, but becomes misfolded in ALS, exposing regions normally buried in its interior. Dr. Neil Cashman, the Chief Scientific Officer of Amorfix, has identified and validated misfolding-exposed regions of SOD1 as novel targets for ALS immunotherapy. In 2010 these targets were sublicensed to Biogen-Idec Corporation for the development of ALS antibody therapeutics and to the Pan provincial Vaccine Enterprise (PREVENT) for the development of vaccine applications.

Dr. Robert Gundel, Amorfix CEO said "Amorfix is very pleased that these US patents for three SOD1 targets in ALS have been awarded giving us a strong patent position in this therapeutic area.  This speaks to the value created by our proprietary ProMIS discovery technology which enables the identification of unique targets for the development of novel therapeutics, vaccines and diagnostics.  We look forward to the approval of other pending applications for additional targets in SOD1 as well as other proteins implicated in misfolded protein diseases such as cancer."

About Amorfix
Amorfix Life Sciences Ltd. (TSX:AMF) is a product development company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including Alzheimer's Disease (AD), cancers, and ALS. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes ("DSEs") on the molecular surface of misfolded proteins. Amorfix's lead programs include therapeutics and companion diagnostics for cancers, antibodies and vaccines to DSEs in ALS and AD diagnostic tests. In addition, Amorfix's proprietary Epitope Protection™ technology enables it to specifically identify very low levels of misfolded proteins in a biological sample. The Company's diagnostic programs include an ultrasensitive method for the detection of aggregated beta-Amyloid in brain tissue, CSF and blood from animal models of AD, months prior to observable amyloid formation, and development of a human screening test for AD. For more information about Amorfix, visit www.amorfix.com.

Forward-Looking Information

This press release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information: